Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28117924 | 0.90 | KMT2A (0.69) | TDP1KMT2ASLC6A2SLC6A3MAPT | |
| SCHEMBL5336730 | 0.89 | KDM4E (0.67) | TDP1KMT2ASLC6A2SLC6A3MAPT | |
| SCHEMBL312910 | 0.88 | TDP1 (0.81) | TDP1KMT2ASLC6A2SLC6A3MAPT | |
| SCHEMBL56565 | 0.83 | RAB9A (0.82) | TDP1KMT2ASLC6A2SLC6A3MAPT | |
| SCHEMBL181934 | 0.83 | TDP1 (0.73) | TDP1KMT2ASLC6A2SLC6A3MAPT | |
| SCHEMBL5335214 | 0.83 | MAPT (0.63) | TDP1KMT2ASLC6A2SLC6A3MAPT | |
| Benzyl Benzoate SCHEMBL8010992 | 0.82 | KMT2A (1.00) | TDP1KMT2ASLC6A2SLC6A3MAPT | |
| Benzyl Benzoate SCHEMBL3038 | 0.82 | KMT2A (1.00) | TDP1KMT2ASLC6A2SLC6A3MAPT | |
| Benzyl Benzoate SCHEMBL901058 | 0.82 | KMT2A (1.00) | TDP1KMT2ASLC6A2SLC6A3MAPT | |
| SCHEMBL318600 | 0.82 | TDP1 (0.71) | TDP1KMT2ASLC6A2SLC6A3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117794526-A | Compositions and methods for antioxidants and anti-inflammatory therapeutics | 阿万蒂生物科学股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-3544979-B1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| WO-2021136805-A1 | NOVEL PqsR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2021-07-08 | — | — | WO | disclosed |
| US-10793561-B2 | 1,8-naphthyridinone compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10329257-B2 | Compositions and methods for treating tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| EP-3456713-A1 | PROCESS FOR THE PREPARATION OF TRIAZINE DERIVATIVES | Japan Tobacco Inc. (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-20190023702-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
| WO-2018081285-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| CN-1374967-A | Compounds for the treatment of ischemia | PFIZER PROD INC (US) | 2002-10-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329257-B2 | Compositions and methods for treating tuberculosis | C5, IFNG, TERT | TDP1 4166/4885KMT2A 3608/4885SLC6A2 4264/4885 |
| US-10793561-B2 | 1,8-naphthyridinone compounds and uses thereof | NME1, ADORA2A, GPR68 | TDP1 1401/4885KMT2A 2285/4885SLC6A2 2928/4885 |
| US-20190023702-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NME1, ADORA2A, GPR68 | TDP1 1401/4885KMT2A 2285/4885SLC6A2 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.